Compare AXGN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 147.4M |
| IPO Year | 2013 | 1999 |
| Metric | AXGN | AGEN |
|---|---|---|
| Price | $40.84 | $3.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $42.33 | $14.50 |
| AVG Volume (30 Days) | ★ 1.0M | 889.8K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $225,208,000.00 | $42,877,086.00 |
| Revenue This Year | $20.57 | $107.63 |
| Revenue Next Year | $16.68 | N/A |
| P/E Ratio | ★ N/A | $3.48 |
| Revenue Growth | 20.21 | ★ 89.95 |
| 52 Week Low | $9.22 | $2.71 |
| 52 Week High | $45.83 | $7.34 |
| Indicator | AXGN | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 45.15 |
| Support Level | $29.48 | $2.91 |
| Resistance Level | $45.14 | $4.25 |
| Average True Range (ATR) | 1.79 | 0.25 |
| MACD | -0.44 | -0.06 |
| Stochastic Oscillator | 23.52 | 35.51 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.